• Chandani Kushwaha
• Yogita Tyagi
• Hiba Parveen
• Praveen Kumar Ashok

Rosacea is a recurring, chronic illness that can cause a wide range of cutaneous symptoms. Financially, physically, and psychologically detrimental are the symptoms of centrofacial inflammatory dermatosis. A variety of topical, oral, and systemic therapies are available. However, rosacea therapy is still challenging. Recently, three clinical trials have exhibited the efficiency of topical ivermectin in treating rosacea. Ivermectin exhibits a broad-spectrum anti-parasitic action, specifically targeting Demodex mites residing within the pilosebaceous cells of individuals with papulopustular rosacea. The application of ivermectin cream successfully eradicates these mites. Ivermectin reduces cellular and humoral immune responses and has anti-inflammatory properties as well. But the currently available treatment methodologies like azelaic acid, brimonidine, oxymetazoline & topical metronidazole which are available in market have various problem related to side effect associated with the use of these drugs. Therefore, to combat these problem associated with the rosacea treatment we have prepared topical ivermectin cream. The main reason for choosing ivermectin is that it has very less side effect on skin in comparison to other available medicaments. Ivermectin 1% cream once daily compared to twice-daily metronidazole 0.75% cream, substantially less inflammatory lesions were present, which was proven to increase the number of IGA patients in a separate phase III study. Ivermectin 1% cream significantly increased patient satisfaction compared to metronidazole 0.75% cream. However, the choice to test metronidazole twice daily rather of a similarly efficient once-day regimen may have had an impact on these evaluations. One advantage of using ivermectin 1% cream is the frequency of once-daily dose, which may increase adherence. Ivermectin 1% cream was determined to have a low probability for side effects in vehicle-controlled phase III trials. There were a small number of participants who suffered mild to moderate adverse responses; these reactions were most frequently characterized by dry skin, pruritus, and skin burning. Further the method was validated by HPLC.

Erythematotelangiectatic, Papulopustular, Phymatous, Robustness

"Formulation and Evaluation of Ivermectin Cream: Method Development and Validation Consideration By HPLC", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 6, page no.j450-j487, June-2023, Available :http://www.jetir.org/papers/JETIR2306957.pdf

"Formulation and Evaluation of Ivermectin Cream: Method Development and Validation Consideration By HPLC", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 6, page no. ppj450-j487, June-2023, Available at : http://www.jetir.org/papers/JETIR2306957.pdf